VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Average Recommendation of “Reduce” from Analysts

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has earned an average rating of “Reduce” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $0.95.

A number of analysts recently issued reports on VTGN shares. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd.

VistaGen Therapeutics Stock Performance

NASDAQ VTGN opened at $0.54 on Wednesday. VistaGen Therapeutics has a 52-week low of $0.43 and a 52-week high of $5.14. The company has a 50-day simple moving average of $0.60 and a 200 day simple moving average of $1.12. The company has a market capitalization of $21.31 million, a PE ratio of -0.28 and a beta of 0.31.

Hedge Funds Weigh In On VistaGen Therapeutics

Large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new position in shares of VistaGen Therapeutics in the first quarter worth about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of VistaGen Therapeutics in the third quarter worth about $39,000. Millennium Management LLC purchased a new position in shares of VistaGen Therapeutics in the third quarter worth about $73,000. Bank of America Corp DE increased its stake in shares of VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of VistaGen Therapeutics in the third quarter worth about $112,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.